An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo

Trial Profile

An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs ATI 502 (Primary)
  • Indications Vitiligo
  • Focus Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 12 Mar 2018 According to an Aclaris Therapeutics media release, data are expected in the first half of 2019
    • 19 Dec 2017 Status changed from planning to recruiting according to an Aclaris Therapeutics media release.
    • 12 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top